Efficacy, safety and pharmacokinetics of sugammadex 4 mg kg−1 for reversal of deep neuromuscular blockade in patients with severe renal impairment

    loading  Checking for direct PDF access through Ovid



This study evaluated efficacy and safety of sugammadex 4 mg kg−1 for deep neuromuscular blockade (NMB) reversal in patients with severe renal impairment (creatinine clearance [CLCR] <30 ml min−1) vs those with normal renal function (CLCR ≥80 ml min−1).


Sugammadex 4 mg kg−1 was administered at 1–2 post-tetanic counts for reversal of rocuronium NMB. Primary efficacy variable was time from sugammadex to recovery to train-of-four (T4/T1) ratio 0.9. Equivalence between groups was demonstrated if two-sided 95% CI for difference in recovery times was within −1 to +1 min interval. Pharmacokinetics of rocuronium and overall safety were assessed.


The intent-to-treat group comprised 67 patients (renal n=35; control n=32). Median (95% CI) time from sugammadex to recovery to T4/T1 ratio 0.9 was 3.1 (2.4–4.6) and 1.9 (1.6–2.8) min for renal patients vs controls. Estimated median (95% CI) difference between groups was 1.3 (0.6–2.4) min; thus equivalence bounds were not met. One control patient experienced acceleromyography-determined NMB recurrence, possibly as a result of premature sugammadex (4 mg kg−1) administration, with no clinical evidence of NMB recurrence observed. Rocuronium, encapsulated by Sugammadex, was detectable in plasma at day 7 in 6 patients. Bioanalytical data for sugammadex were collected but could not be used for pharmacokinetics.


Sugammadex 4 mg kg−1 provided rapid reversal of deep rocuronium-induced NMB in renal and control patients. However, considering the prolonged sugammadex-rocuronium complex exposure in patients with severe renal impairment, current safety experience is insufficient to support recommended use of sugammadex in this population.

Clinical trial registration


Related Topics

    loading  Loading Related Articles